Egyptian International Pharmaceutical Investments (CAI:PHAR) Interest Expense : E£-389 Mil (TTM As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is Egyptian International Pharmaceutical Investments Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Egyptian International Pharmaceutical Investments's interest expense for the three months ended in Dec. 2023 was E£ -123 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was E£-389 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Egyptian International Pharmaceutical Investments's Operating Income for the three months ended in Dec. 2023 was E£ 380 Mil. Egyptian International Pharmaceutical Investments's Interest Expense for the three months ended in Dec. 2023 was E£ -123 Mil. Egyptian International Pharmaceutical Investments's Interest Coverage for the quarter that ended in Dec. 2023 was 3.08. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Egyptian International Pharmaceutical Investments Interest Expense Historical Data

The historical data trend for Egyptian International Pharmaceutical Investments's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Egyptian International Pharmaceutical Investments Interest Expense Chart

Egyptian International Pharmaceutical Investments Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-61.69

-109.54

-136.25

-195.42

-388.52

Egyptian International Pharmaceutical Investments Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-91.84	-72.36	-85.28	-107.58	-123.30

Egyptian International Pharmaceutical Investments Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was E£-389 Mil.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Egyptian International Pharmaceutical Investments's Interest Expense for the three months ended in Dec. 2023 was E£-123 Mil. Its Operating Income for the three months ended in Dec. 2023 was E£380 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was E£2,832 Mil.

Egyptian International Pharmaceutical Investments's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	380.221	/	-123.301
	=	3.08

The higher the ratio, the stronger the company's financial strength is.

Egyptian International Pharmaceutical Investments (CAI:PHAR) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Egyptian International Pharmaceutical Investments (CAI:PHAR) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

1st Industrial Zone B1, EIPICO, 10th of Ramadan, EGY

Website

http://www.eipico.com.eg

Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, non-traditional dosage forms including soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets. It exports its products to Arab countries, African, Asian and East European Countries. Its products portfolio includes antibiotics, anesthetics, analgesics, antihypertensives, cholesterol-lowering medications, ophthalmic products, blood substitutes and restoratives, dermatological drugs and vitamins. Some of its products are Vasotec, Co-vasotec, Flumox, and Cefotax.